Physician profile
Jay Willis Porter
NPI 1699745299
$5,386.61
in general payments reported to CMS, 2019-2025
30 companies · $84.88 in 2025
The $84.88 reported for 2025 was less than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $391 · 2020: $1,003 · 2021: $1,013 · 2022: $965 · 2023: $1,041 · 2024: $889 · 2025: $84.88.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,992 · Education: $22.80.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,992.17 |
| Education | $22.80 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $1,049.62 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Lilly USA, LLC | $624.99 | 2019-2024 | Mounjaro, Zepbound, Jardiance |
| Glaxosmithkline, LLC. | $585.45 | 2019-2024 | Trelegy Ellipta, Shingrix, Arexvy |
| Abbvie INC. | $543.03 | 2019-2025 | |
| Pfizer INC. | $533.04 | 2019-2024 | |
| Astrazeneca Pharmaceuticals Lp | $348.22 | 2019-2024 | Farxiga |
| Boehringer Ingelheim Pharmaceuticals, INC. | $245.87 | 2020-2023 | Jardiance |
| Merck Sharp & Dohme LLC | $232.93 | 2019-2024 | Gardasil 9, M-M-R II, Rotateq |
| Amarin Pharma, INC. | $188.02 | 2020-2022 | |
| E.R. Squibb & Sons, L.L.C. | $138.92 | 2019-2024 | Eliquis, Camzyos |
| Exact Sciences Corporation | $92.74 | 2023-2024 | Cologuard Collection Kit |
| Bayer Healthcare Pharmaceuticals INC. | $92.15 | 2023-2025 | |
| Abbott Laboratories | $78.11 | 2021-2023 | Freestyle Libre 3 |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $75.73 | 2023-2024 | Xifaxan, Trulance |
| Janssen Pharmaceuticals, INC | $70.98 | 2020-2021 |
Show all 30 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Shield Therapeutics INC | $55.67 | 2023-2024 | Accrufer |
| Amgen INC. | $48.10 | 2020-2024 | Repatha, Otezla |
| Dexcom, INC. | $44.10 | 2023-2024 | Dexcom G6 Transmitter |
| Astellas Pharma US INC | $40.62 | 2022 | |
| Xeris Pharmaceuticals, INC. | $40.15 | 2021-2024 | Gvoke Hypopen |
| Sunovion Pharmaceuticals INC. | $35.87 | 2021-2022 | |
| Mylan Specialty L.P. | $32.74 | 2024 | Yupelri |
| Inspire Medical Systems, INC. | $31.75 | 2023 | Inspire |
| Edwards Lifesciences Corporation | $29.84 | 2022 | |
| Sanofi-Aventis U.S. LLC | $28.87 | 2019-2021 | |
| Neurelis, INC. | $27.14 | 2023 | Valtoco |
| Boston Scientific Corporation | $21.08 | 2022 | |
| Esperion Therapeutics, INC. | $17.30 | 2021 | |
| Tactile Systems Technology INC | $17.04 | 2022 | |
| Novartis Pharmaceuticals Corporation | $16.54 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jay Porter listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.